United Therapeutics Corporation Revenue
United Therapeutics Corporation (UTHR) reported Revenue of $783.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $783.30M, a 1.92% decline year-over-year.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $781.50M, a 1.62% decline year-over-year.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $790.20M, a 7.38% increase year-over-year.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $799.50M, a 6.76% increase year-over-year.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2025 was $3.18B, a 10.61% increase from fiscal 2024.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.88B, a 23.63% increase from fiscal 2023.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.33B, a 20.20% increase from fiscal 2022.
- United Therapeutics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.94B, a 14.88% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $783.30M 10-Q · filed 2026-08-05 | $1.56B 10-Q · filed 2026-08-05 | $2.35B derived: sum of 3 quarters · filed 2026-08-05 | $3.15B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $781.50M 10-Q · filed 2026-05-06 | $1.57B derived: sum of 2 quarters · filed 2026-05-06 | $2.37B derived: sum of 3 quarters · filed 2026-05-06 | $3.17B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $790.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.59B derived: sum of 2 quarters · filed 2026-02-25 | $2.39B derived: sum of 3 quarters · filed 2026-08-05 | $3.18B 10-K · filed 2026-02-25 |
| 2025-09-30 | $799.50M 10-Q · filed 2025-10-29 | $1.60B derived: sum of 2 quarters · filed 2026-08-05 | $2.39B 10-Q · filed 2025-10-29 | $3.13B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $798.60M 10-Q · filed 2026-08-05 | $1.59B 10-Q · filed 2026-08-05 | $2.33B derived: sum of 3 quarters · filed 2026-08-05 | $3.08B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $794.40M 10-Q · filed 2026-05-06 | $1.53B derived: sum of 2 quarters · filed 2026-05-06 | $2.28B derived: sum of 3 quarters · filed 2026-05-06 | $2.99B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $735.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.48B derived: sum of 2 quarters · filed 2026-02-25 | $2.20B derived: sum of 3 quarters · filed 2026-02-25 | $2.88B 10-K · filed 2026-02-25 |
| 2024-09-30 | $748.90M 10-Q · filed 2025-10-29 | $1.46B derived: sum of 2 quarters · filed 2025-10-29 | $2.14B 10-Q · filed 2025-10-29 | $2.76B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $714.90M 10-Q · filed 2025-07-30 | $1.39B 10-Q · filed 2025-07-30 | $2.01B derived: sum of 3 quarters · filed 2026-02-25 | $2.62B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $677.70M 10-Q · filed 2025-04-30 | $1.29B derived: sum of 2 quarters · filed 2026-02-25 | $1.90B derived: sum of 3 quarters · filed 2026-02-25 | $2.50B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $614.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.22B derived: sum of 2 quarters · filed 2026-02-25 | $1.82B derived: sum of 3 quarters · filed 2026-02-25 | $2.33B 10-K · filed 2026-02-25 |
| 2023-09-30 | $609.40M 10-Q · filed 2024-10-30 | $1.21B derived: sum of 2 quarters · filed 2024-10-30 | $1.71B 10-Q · filed 2024-10-30 | $2.20B derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $596.50M 10-Q · filed 2024-07-31 | $1.10B 10-Q · filed 2024-07-31 | $1.59B derived: sum of 3 quarters · filed 2025-02-26 | $2.11B derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $506.90M 10-Q · filed 2024-05-01 | $998.40M derived: sum of 2 quarters · filed 2025-02-26 | $1.51B derived: sum of 3 quarters · filed 2025-02-26 | $1.98B derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $491.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.01B derived: sum of 2 quarters · filed 2025-02-26 | $1.47B derived: sum of 3 quarters · filed 2025-02-26 | $1.94B 10-K · filed 2025-02-26 |
| 2022-09-30 | $516.00M 10-Q · filed 2023-11-01 | $982.90M derived: sum of 2 quarters · filed 2023-11-01 | $1.44B 10-Q · filed 2023-11-01 | $1.86B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $466.90M 10-Q · filed 2023-08-02 | $928.80M 10-Q · filed 2023-08-02 | $1.34B derived: sum of 3 quarters · filed 2024-02-21 | $1.79B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $461.90M 10-Q · filed 2023-05-03 | $877.10M derived: sum of 2 quarters · filed 2024-02-21 | $1.32B derived: sum of 3 quarters · filed 2024-02-21 | $1.77B derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $415.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $859.90M derived: sum of 2 quarters · filed 2024-02-21 | $1.31B derived: sum of 3 quarters · filed 2024-02-21 | $1.69B 10-K · filed 2024-02-21 |
| 2021-09-30 | $444.70M 10-Q · filed 2022-11-02 | $891.20M derived: sum of 2 quarters · filed 2022-11-02 | $1.27B 10-Q · filed 2022-11-02 | $1.66B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $446.50M 10-Q · filed 2022-08-03 | $825.60M 10-Q · filed 2022-08-03 | $1.21B derived: sum of 3 quarters · filed 2023-02-22 | $1.59B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $379.10M 10-Q · filed 2022-05-04 | $764.00M derived: sum of 2 quarters · filed 2023-02-22 | $1.14B derived: sum of 3 quarters · filed 2023-02-22 | $1.51B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $384.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $765.00M derived: sum of 2 quarters · filed 2023-02-22 | $1.13B derived: sum of 3 quarters · filed 2023-02-22 | $1.48B 10-K · filed 2023-02-22 |
| 2020-09-30 | $380.10M 10-Q · filed 2021-11-03 | $742.10M derived: sum of 2 quarters · filed 2021-11-03 | $1.10B 10-Q · filed 2021-11-03 | $1.41B derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $362.00M 10-Q · filed 2021-08-04 | $718.30M 10-Q · filed 2021-08-04 | $1.03B derived: sum of 3 quarters · filed 2022-02-24 | $1.43B derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $356.30M 10-Q · filed 2021-05-05 | $667.40M derived: sum of 2 quarters · filed 2022-02-24 | $1.07B derived: sum of 3 quarters · filed 2022-02-24 | $1.44B derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $311.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $712.60M derived: sum of 2 quarters · filed 2022-02-24 | $1.09B derived: sum of 3 quarters · filed 2022-02-24 | $1.45B 10-K · filed 2022-02-24 |
| 2019-09-30 | $401.50M 10-Q · filed 2020-10-28 | $775.10M derived: sum of 2 quarters · filed 2020-10-28 | $1.14B 10-Q · filed 2020-10-28 | $1.52B derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $373.60M 10-Q · filed 2020-07-29 | $736.20M 10-Q · filed 2020-07-29 | $1.12B derived: sum of 3 quarters · filed 2021-02-24 | $1.53B derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $362.60M 10-Q · filed 2020-04-29 | $744.00M derived: sum of 2 quarters · filed 2021-02-24 | $1.16B derived: sum of 3 quarters · filed 2021-02-24 | $1.60B derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $381.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $794.10M derived: sum of 2 quarters · filed 2021-02-24 | $1.24B derived: sum of 3 quarters · filed 2021-02-24 | $1.63B 10-K · filed 2021-02-24 |
| 2018-09-30 | $412.70M 10-Q · filed 2019-10-30 | $857.20M derived: sum of 2 quarters · filed 2019-10-30 | $1.25B 10-Q · filed 2019-10-30 | $1.71B derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $444.50M 10-Q · filed 2019-07-31 | $833.70M 10-Q · filed 2019-07-31 | $1.30B derived: sum of 3 quarters · filed 2020-02-26 | $1.74B derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $389.20M 10-Q · filed 2019-05-01 | $853.90M derived: sum of 2 quarters · filed 2020-02-26 | $1.30B derived: sum of 3 quarters · filed 2020-02-26 | $1.74B derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $464.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $910.20M derived: sum of 2 quarters · filed 2020-02-26 | $1.35B derived: sum of 3 quarters · filed 2020-02-26 | $1.73B 10-K · filed 2020-02-26 |
| 2017-09-30 | $445.50M 10-Q · filed 2018-10-31 | $890.10M derived: sum of 2 quarters · filed 2018-10-31 | $1.26B 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $444.60M 10-Q · filed 2018-08-01 | $815.10M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $370.50M 10-Q · filed 2018-05-02 | |||
| 2016-12-31 | $1.60B 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |